Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4610805 | 1.00 | TACR2 (0.62) | TACR2TACR1 | |
| SCHEMBL8870093 | 1.00 | TACR2 (0.62) | TACR2TACR1 | |
| SCHEMBL9110425 | 0.89 | TACR2 (0.61) | TACR2TACR1 | |
| SCHEMBL8580532 | 0.89 | TACR2 (0.51) | TACR2TACR1 | |
| SCHEMBL8332427 | 0.88 | TACR2 (0.49) | TACR2TACR1 | |
| SCHEMBL8069511 | 0.88 | TACR2 (0.49) | TACR2TACR1 | |
| SCHEMBL8063574 | 0.87 | TACR2 (0.48) | TACR2TACR1 | |
| SCHEMBL8053254 | 0.87 | TACR2 (0.48) | TACR2TACR1 | |
| SCHEMBL6663184 | 0.86 | TACR2 (0.46) | TACR2TACR1 | |
| SCHEMBL4257408 | 0.86 | TACR2 (0.46) | TACR2TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7368461-B2 | Compounds and method for the treatment of overactive bladder | ASTRAZENECA AB (SE) | 2008-05-06 | — | — | US | disclosed |
| WO-2007088181-A1 | NOVEL DUAL NK2/NK3-ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND PROCESSES FOR THEIR PREPARATIONS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-08-09 | — | — | WO | disclosed |
| EP-1444220-B1 | COMPOUNDS AND METHOD FOR THE TREATMENT OF OVERACTIVE BLADDER | ASTRAZENECA AB (SE) | 2007-02-14 | — | — | EP | disclosed |
| EP-1307202-B1 | METHOD FOR THE TREATMENT OF OVERACTIVE BLADDER | ASTRAZENECA AB (SE) | 2006-05-17 | — | — | EP | disclosed |
| US-20050203113-A1 | Compounds and method for the treatment of overactive bladder | ASTRAZENECA AB (SE) | 2005-09-15 | — | — | US | disclosed |
| US-20040248914-A1 | Method for the treatment of overactive bladder | ASTRAZENECA AB (SE) | 2004-12-09 | — | — | US | disclosed |
| EP-1450805-A1 | METHOD FOR THE TREATMENT OF OVERACTIVE BLADDER | AstraZeneca AB (SE) | 2004-09-01 | — | — | EP | disclosed |
| EP-1444220-A1 | COMPOUNDS AND METHOD FOR THE TREATMENT OF OVERACTIVE BLADDER | AstraZeneca AB (SE) | 2004-08-11 | — | — | EP | disclosed |
| US-20030187255-A1 | Therapeutic heterocycles | MILLER SCOTT CARSON (US) | 2003-10-02 | — | — | US | disclosed |
| US-20030139433-A1 | Method for the treatment of overactive bladder | ASTRAZENECA AB (SE) | 2003-07-24 | — | — | US | disclosed |
| EP-0714392-A1 | HETEROCYCLES USEFUL AS NEUROKININ ANTAGONISTS | ZENECA LIMITED (GB) | 1996-06-05 | — | — | EP | disclosed |
| US-5521199-A | TREATMENT OF ASTHMA | ZENECA LIMITED (GB) | 1996-05-28 | — | — | US | disclosed |
| EP-0681571-A1 | SPIRO-SUBSTITUTED AZACYCLES AS TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO. INC. (US) | 1995-11-15 | — | — | EP | disclosed |
| EP-0667858-A1 | 4-CARBOXOAMIDO PIPERIDINE DERIVATIVES, INTERMEDIATES AND USE AS NEUROKININ ANTAGONISTS | ZENECA LIMITED (GB) | 1995-08-23 | — | — | EP | disclosed |
| WO-1995015961-A1 | BICYCLIC HETEROCYCLES AS NEUROKININ A ANTAGONISTS | ZENECA LIMITED (GB) | 1995-06-15 | — | — | WO | disclosed |
| WO-1995012577-A1 | NOVEL 4-PIPERIDINYL SUBSTITUTED LACTAMES AS NEUROKININ 2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF ASTHMA | ZENECA LIMITED (GB) | 1995-05-11 | — | — | WO | disclosed |
| WO-1995005377-A1 | HETEROCYCLES USEFUL AS NEUROKININ ANTAGONISTS | ZENECA LIMITED (GB) | 1995-02-23 | — | — | WO | disclosed |
| CN-1094723-A | Carboxamide derivative | ZENECA LTD (GB) | 1994-11-09 | — | — | CN | disclosed |
| WO-1994017045-A1 | SPIRO-SUBSTITUTED AZACYCLES AS TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1994-08-04 | — | — | WO | disclosed |
| WO-1994010146-A1 | 4-CARBOXOAMIDO PIPERIDINE DERIVATIVES, INTERMEDIATES AND USE AS NEUROKININ ANTAGONISTS | ZENECA LIMITED (GB) | 1994-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248914-A1 | Method for the treatment of overactive bladder | TACR1, TACR2, OGFR | TACR2 2/4885TACR1 1/4885 |
| US-20030139433-A1 | Method for the treatment of overactive bladder | QDPR, PDE3A, HNMT | TACR2 75/4885TACR1 35/4885 |
| US-20030187255-A1 | Therapeutic heterocycles | BDKRB2, TK2, TACR2 | TACR2 3/4885TACR1 21/4885 |
| US-20050203113-A1 | Compounds and method for the treatment of overactive bladder | TACR1, TACR2, BDKRB1 | TACR2 2/4885TACR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.